Education/CredentialsPhD: The Catholic University of America (Cellular and Microbial Biology)MS: Johns Hopkins University (Biotechnology)BS: James Madison University (Integrated Science and Technology: Biotechnology) Contact Information Vontz Center 2124 Email watersa3@ucmail.uc.edu Research InterestsKRAS-mutant cancers MYC Pancreatic Cancer Lung Cancer Colorectal Cancer Peer Reviewed Publications Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Hibshman, Priya S; Stalnecker, Clint A; Klomp, Jeffrey A; Drizyte-Miller, Kristina; Klomp, Jennifer E; Edwards, A Cole; Pita, Lily M; Hodge, Richard G; Diehl, J Nathaniel; Mouery, Ryan D; Mouery, Brandon L; Snare, Kayla R; Waters, Andrew M; Peng, Sen; Barker, Natalie K; Pierobon, Mariaelena; Rashid, Naim U; Tran, Nhan L; Herring, Laura A; Graves, Lee M; Petricoin, Emanuel F; Bryant, Kirsten L; Cox, Adrienne D; Der, Channing J 2025. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Science signaling, 18 906, eadu7145Long S-A, Todd H, Goodhart G, Chang W-H, Amparo AM, Bridgens R, Dilly J, Park S-J, Beal RM, Shehadeh SM, Satyadi MA, Trivedi VK, Ackermann SE, Mukherjee R, Goodwin CM, Edwards AC, Stalnecker CA, Greis KD, Aguirre AJ, Hobbs GA, Bryant KL, Ahmad SA, Cox AD, Der CJ, Waters AM 2025. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer Cancer Research, , Loveless, Ian M; Kemp, Samantha B; Hartway, Kailee M; Mitchell, Jacob T; Wu, Yuesong; Zwernik, Samuel D; Salas-Escabillas, Daniel James; Brender, Sydney; George, Madison; Makinwa, Yetunde; Stockdale, Thais; Gartrelle, Kendyll; Reddy, Rohit G; Long, Daniel W; Wombwell, Allison; Clark, Julie M; Levin, Albert M; Kwon, David; Huang, Ling; Francescone, Ralph; Vendramini-Costa, Debora B; Stanger, Ben; Alessio, Adam; Waters, Andrew M; Cui, Yuehua; Fertig, Elana J; Kagohara, Luciane T; Theisen, Brian; Crawford, Howard C; Steele, Nina G 2025. Human pancreatic cancer single cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research, , Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika 2024. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature, , Long, Szu-Aun; Amparo, Amber M; Goodhart, Grace; Ahmad, Syed A; Waters, Andrew M 2024. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in oncology, 14 , 1402128Nussbaum, Daniel P; Martz, Colin A; Waters, Andrew M; Barrera, Alejandro; Liu, Annie; Rutter, Justine C; Cerda-Smith, Christian G; Stewart, Amy E; Wu, Chao; Cakir, Merve; Levandowski, Cecilia B; Kantrowitz, David E; McCall, Shannon J; Pierobon, Mariaelena; Petricoin, Emanuel F; Joshua Smith, J; Reddy, Timothy E; Der, Channing J; Taatjes, Dylan J; Wood, Kris C 2024. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers. NPJ precision oncology, 8 1, 124Edwards, A Cole; Stalnecker, Clint A; Jean Morales, Alexis; Taylor, Khalilah E; Klomp, Jennifer E; Klomp, Jeffrey A; Waters, Andrew M; Sudhakar, Niranjan; Hallin, Jill; Tang, Tracy T; Olson, Peter; Post, Leonard; Christensen, James G; Cox, Adrienne D; Der, Channing J 2023. TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer research, , Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J 2023. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer research, 83 1, 141-157Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J 2022. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer research, 82 1, 90-104Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J 2022. Functional and biological heterogeneity of KRASQ61 mutations. Science signaling, 15 746, eabn2694Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D 2022. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 21 5, 762-774Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J 2021. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37 9, 110060Waters, Andrew M; Der, Channing J 2021. Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in molecular biology (Clifton, N.J.), 2262 , 91-103Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J 2021. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35 13, 109291Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2020. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 26 6, 982Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J 2020. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery, 10 1, 104-123Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J 2020. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31 11, 107764Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2019. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 25 4, 628-640Waters, Andrew M; Der, Channing J 2018. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor perspectives in medicine, 8 9, Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank 2018. Differential Effector Engagement by Oncogenic KRAS. Cell reports, 22 7, 1889-1902Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science signaling, 10 498, Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip 2016. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 7 52, 86948-86971Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L . Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PloS one, 11 9, e0163272
Peer Reviewed Publications Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Hibshman, Priya S; Stalnecker, Clint A; Klomp, Jeffrey A; Drizyte-Miller, Kristina; Klomp, Jennifer E; Edwards, A Cole; Pita, Lily M; Hodge, Richard G; Diehl, J Nathaniel; Mouery, Ryan D; Mouery, Brandon L; Snare, Kayla R; Waters, Andrew M; Peng, Sen; Barker, Natalie K; Pierobon, Mariaelena; Rashid, Naim U; Tran, Nhan L; Herring, Laura A; Graves, Lee M; Petricoin, Emanuel F; Bryant, Kirsten L; Cox, Adrienne D; Der, Channing J 2025. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Science signaling, 18 906, eadu7145Long S-A, Todd H, Goodhart G, Chang W-H, Amparo AM, Bridgens R, Dilly J, Park S-J, Beal RM, Shehadeh SM, Satyadi MA, Trivedi VK, Ackermann SE, Mukherjee R, Goodwin CM, Edwards AC, Stalnecker CA, Greis KD, Aguirre AJ, Hobbs GA, Bryant KL, Ahmad SA, Cox AD, Der CJ, Waters AM 2025. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer Cancer Research, , Loveless, Ian M; Kemp, Samantha B; Hartway, Kailee M; Mitchell, Jacob T; Wu, Yuesong; Zwernik, Samuel D; Salas-Escabillas, Daniel James; Brender, Sydney; George, Madison; Makinwa, Yetunde; Stockdale, Thais; Gartrelle, Kendyll; Reddy, Rohit G; Long, Daniel W; Wombwell, Allison; Clark, Julie M; Levin, Albert M; Kwon, David; Huang, Ling; Francescone, Ralph; Vendramini-Costa, Debora B; Stanger, Ben; Alessio, Adam; Waters, Andrew M; Cui, Yuehua; Fertig, Elana J; Kagohara, Luciane T; Theisen, Brian; Crawford, Howard C; Steele, Nina G 2025. Human pancreatic cancer single cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research, , Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika 2024. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature, , Long, Szu-Aun; Amparo, Amber M; Goodhart, Grace; Ahmad, Syed A; Waters, Andrew M 2024. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in oncology, 14 , 1402128Nussbaum, Daniel P; Martz, Colin A; Waters, Andrew M; Barrera, Alejandro; Liu, Annie; Rutter, Justine C; Cerda-Smith, Christian G; Stewart, Amy E; Wu, Chao; Cakir, Merve; Levandowski, Cecilia B; Kantrowitz, David E; McCall, Shannon J; Pierobon, Mariaelena; Petricoin, Emanuel F; Joshua Smith, J; Reddy, Timothy E; Der, Channing J; Taatjes, Dylan J; Wood, Kris C 2024. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers. NPJ precision oncology, 8 1, 124Edwards, A Cole; Stalnecker, Clint A; Jean Morales, Alexis; Taylor, Khalilah E; Klomp, Jennifer E; Klomp, Jeffrey A; Waters, Andrew M; Sudhakar, Niranjan; Hallin, Jill; Tang, Tracy T; Olson, Peter; Post, Leonard; Christensen, James G; Cox, Adrienne D; Der, Channing J 2023. TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer research, , Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J 2023. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer research, 83 1, 141-157Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J 2022. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer research, 82 1, 90-104Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J 2022. Functional and biological heterogeneity of KRASQ61 mutations. Science signaling, 15 746, eabn2694Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D 2022. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 21 5, 762-774Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J 2021. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37 9, 110060Waters, Andrew M; Der, Channing J 2021. Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in molecular biology (Clifton, N.J.), 2262 , 91-103Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J 2021. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35 13, 109291Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2020. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 26 6, 982Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J 2020. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery, 10 1, 104-123Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J 2020. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31 11, 107764Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2019. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 25 4, 628-640Waters, Andrew M; Der, Channing J 2018. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor perspectives in medicine, 8 9, Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank 2018. Differential Effector Engagement by Oncogenic KRAS. Cell reports, 22 7, 1889-1902Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science signaling, 10 498, Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip 2016. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 7 52, 86948-86971Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L . Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PloS one, 11 9, e0163272
Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Alharbi, Sara; Merkle, Svatava; Hammill, Adrienne M; Waters, Andrew M; Le Cras, Timothy D 2025. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric blood & cancer, 72 5, e31605Hibshman, Priya S; Stalnecker, Clint A; Klomp, Jeffrey A; Drizyte-Miller, Kristina; Klomp, Jennifer E; Edwards, A Cole; Pita, Lily M; Hodge, Richard G; Diehl, J Nathaniel; Mouery, Ryan D; Mouery, Brandon L; Snare, Kayla R; Waters, Andrew M; Peng, Sen; Barker, Natalie K; Pierobon, Mariaelena; Rashid, Naim U; Tran, Nhan L; Herring, Laura A; Graves, Lee M; Petricoin, Emanuel F; Bryant, Kirsten L; Cox, Adrienne D; Der, Channing J 2025. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Science signaling, 18 906, eadu7145Long S-A, Todd H, Goodhart G, Chang W-H, Amparo AM, Bridgens R, Dilly J, Park S-J, Beal RM, Shehadeh SM, Satyadi MA, Trivedi VK, Ackermann SE, Mukherjee R, Goodwin CM, Edwards AC, Stalnecker CA, Greis KD, Aguirre AJ, Hobbs GA, Bryant KL, Ahmad SA, Cox AD, Der CJ, Waters AM 2025. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer Cancer Research, , Loveless, Ian M; Kemp, Samantha B; Hartway, Kailee M; Mitchell, Jacob T; Wu, Yuesong; Zwernik, Samuel D; Salas-Escabillas, Daniel James; Brender, Sydney; George, Madison; Makinwa, Yetunde; Stockdale, Thais; Gartrelle, Kendyll; Reddy, Rohit G; Long, Daniel W; Wombwell, Allison; Clark, Julie M; Levin, Albert M; Kwon, David; Huang, Ling; Francescone, Ralph; Vendramini-Costa, Debora B; Stanger, Ben; Alessio, Adam; Waters, Andrew M; Cui, Yuehua; Fertig, Elana J; Kagohara, Luciane T; Theisen, Brian; Crawford, Howard C; Steele, Nina G 2025. Human pancreatic cancer single cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research, , Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika 2024. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature, , Long, Szu-Aun; Amparo, Amber M; Goodhart, Grace; Ahmad, Syed A; Waters, Andrew M 2024. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Frontiers in oncology, 14 , 1402128Nussbaum, Daniel P; Martz, Colin A; Waters, Andrew M; Barrera, Alejandro; Liu, Annie; Rutter, Justine C; Cerda-Smith, Christian G; Stewart, Amy E; Wu, Chao; Cakir, Merve; Levandowski, Cecilia B; Kantrowitz, David E; McCall, Shannon J; Pierobon, Mariaelena; Petricoin, Emanuel F; Joshua Smith, J; Reddy, Timothy E; Der, Channing J; Taatjes, Dylan J; Wood, Kris C 2024. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers. NPJ precision oncology, 8 1, 124Edwards, A Cole; Stalnecker, Clint A; Jean Morales, Alexis; Taylor, Khalilah E; Klomp, Jennifer E; Klomp, Jeffrey A; Waters, Andrew M; Sudhakar, Niranjan; Hallin, Jill; Tang, Tracy T; Olson, Peter; Post, Leonard; Christensen, James G; Cox, Adrienne D; Der, Channing J 2023. TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer research, , Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J 2023. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer research, 83 1, 141-157Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J 2022. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer research, 82 1, 90-104Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J 2022. Functional and biological heterogeneity of KRASQ61 mutations. Science signaling, 15 746, eabn2694Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D 2022. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 21 5, 762-774Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J 2021. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37 9, 110060Waters, Andrew M; Der, Channing J 2021. Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in molecular biology (Clifton, N.J.), 2262 , 91-103Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J 2021. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35 13, 109291Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2020. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 26 6, 982Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J 2020. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery, 10 1, 104-123Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J 2020. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31 11, 107764Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J 2019. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature medicine, 25 4, 628-640Waters, Andrew M; Der, Channing J 2018. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor perspectives in medicine, 8 9, Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank 2018. Differential Effector Engagement by Oncogenic KRAS. Cell reports, 22 7, 1889-1902Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science signaling, 10 498, Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip 2016. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 7 52, 86948-86971Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L . Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PloS one, 11 9, e0163272